La chaîne d'options affiche les données clés des options sur actions de Dare Bioscience à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Dare Bioscience..

Dare Bioscience (NASDAQ:DARE) Stock, Chaîne d'Options

DARE BIOSCIENCE INC

Dare Bioscience

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

On July 15, 2025, BioXcel Therapeutics, Inc. announced that the United States Patent and Trademark Office had allowed U.S. Patent Application No. 18/600,419 with claims pertaining to the administration of a single dose of up to 120 mcg of dexmedetomidine in an oromucosal formulation for the treatment of acute agitation associated with schizophrenia or bipolar disorder in certain patient subpopulations where the patient exhibits a maximum allowed QT prolongation of less than six microseconds. The allowed claims mirror the recommended IGALMI dosing regime for treatment of patients meeting this QT prolongation criteria. Once issued, this patent will be eligible for listing in the Orange Book for Igalmi and will be the 14th Orange Book listed patent for Igalmi. This patent will have an expiry date of January 12, 2043, subject to patent term adjustment.

Biotech

News

General

BTAI

UPDATE: BioXcel Therapeutics Receives USPTO Approval For IGALMI Patent Application Covering Specific Dosing Regimen, Eligible for Orange Book Listing Through 2043

U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.31% to 44,320.60 while the NASDAQ gained 0.70% to 20,784.40. The S&amp;P 500 also rose, gaining, 0.24% to 6,283.58.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46413798/morgan-stanley-how-to-earn-500-a-month-from-q2-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q2 Earnings</a>
Leading and Lagging Sectors Information technology shares jumped by 1.6% on Tuesday.
In trading on Tuesday, financial stocks dipped by 1.1%.
Top Headline
JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported better-than-expected second-quarter earnings.
JPMorgan Chase reported quarterly earnings of $4.96 per share which beat the analyst consensus estimate of $4.48 per share. The company reported quarterly sales of $45.680 billion which beat the analyst consensus estimate of $44.167 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares shot up 189% to $7.64 after the company announced it has entered into a definitive merger agreement with True Health.</li>
<li>Shares of Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) got a boost, surging 100% to $1.36 after the company announced safety results from its Phase 2 trial of ENV-105 in advanced prostate cancer.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares were also up, gaining 78% to $0.2670 after the company announced it is partnering with HYPERCOMMUNITY to deliver an AI-driven VTuber platform.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Ryvyl Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) shares dropped 43% to $0.37 after the company announced the pricing of its $6 million offering of 15,384,615 shares and warrants at $0.39 per share and accompanying warrant.</li>
<li>Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) were down 41% to $0.4102 after the company announced the pricing of $3.0 million registered direct offering.</li>
<li>TROOPS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROO#NASDAQ">TROO</a>) was down, falling 34% to $0.8786.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $66.91 while gold traded down 0.2% at $3,353.80.
Silver traded down 0.4% to $38.575 on Tuesday, while copper rose 0.1% to $5.5535.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.2%, while Spain's IBEX 35 Index fell 0.7%. London's FTSE 100 rose 0.1%, Germany's DAX 40 gained 0.2% and France's CAC 40 rose 0.1% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei gaining 0.55%, Hong Kong's Hang Seng gaining 1.60%, China's Shanghai Composite falling 0.42% and India's BSE Sensex gaining 0.39%.
Economics
The New York Empire State Manufacturing Index jumped to 5.5 in July, compared to a reading of -16.0 in June and topping market estimates of -9.0.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46414893/meta-to-rally-around-8-here-are-10-top-analyst-forecasts-for-tuesday">Meta To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BLMZ

KAPA

RANI

RVYL

TROO

Longevity Health Holdings, Inc. - Common Stock

XAGE

Dow Falls Over 100 Points; JPMorgan Posts Upbeat Earnings

SRx Health Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRXH#NYSE">SRXH</a>) (the "Company"), a leading global health and wellness company, today announced the appointment of current President, Kent Cunningham, as CEO, and current CEO, Adesh Vora, as Vice Chairman effective immediately.

Management

SRXH

SRx Health Solutions Announces The Appointment Of Current President, Kent Cunningham, As CEO; Current CEO, Adesh Vora, As Vice Chairman, Both Effective Immediately

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) traded higher in premarket on Tuesday after reporting <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46410863/jpmorganchase-reports-second-quarter-2025-financial-results" rel="noreferrer noopener">second-quarter 2025 results</a> that beat revenue and earnings estimates.
Managed net Revenue fell 10% year over year to $45.68 billion. Reported net Revenue declined 11% to $44.91 billion, topping the consensus estimate of $44.17 billion. Adjusted EPS of $4.96 exceeded the consensus of $4.48.
Consumer &amp; Community Banking (CCB) revenue rose 6% YoY to $18.8 billion, and Commercial &amp; Investment Bank (CIB) revenue was $19.5 billion (+9% Y/Y) in the quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46407556/jamie-dimon-will-go-all-in-on-crypto-says-jim-cramer-after-bitcoins-explosive-rally-id-like-to-pay-the-bookie" rel="noreferrer noopener">Jamie Dimon Will &#8216;Go All In On Crypto,&#8217; Says Jim Cramer After Bitcoin&#8217;s Explosive Rally: &#8216;I&#8217;d Like To Pay The Bookie…</a>&#8216;
Investment Banking revenue was $2.7 billion, up 9% YoY, in the quarter. Payments revenue grew 4% to $4.7 billion, up 3% ex-equity gains, driven by deposits and fees. Lending Revenue fell 6% YoY to $1.8 billion.
Asset and Wealth Management (AWM) Revenue was $5.8 billion (+10% YoY), driven by higher fees from inflows, market gains, brokerage activity, and deposit balances.
Corporate Revenue fell to $1.5 billion, down $8.6 billion year over year. Net interest income dropped $875 million to $1.5 billion, while noninterest Revenue declined $7.7 billion to $49 million, mainly due to last year&#8217;s Visa gain.
In AWM, Assets under management stood at $4.343 trillion, and client assets stood at $6.42 trillion (up 19%), driven by higher market levels and continued net inflows.
Net interest income excluding Markets slipped 1% to $22.8 billion, as higher wholesale and card balances mostly offset lower rates and margin compression.
Noninterest Revenue excluding Markets fell 31% to $14.0 billion but rose 8% adjusted for last year&#8217;s Visa gain and securities losses, driven by growth in fees across asset management, auto leases, investment banking, and Payments. Markets revenue rose 15% to $8.90 billion.
The provision for credit losses was $2.85 billion, down 7% YoY, with $2.4 billion in charge-offs (up $179M) and a $439 million reserve build tied to lending growth. A year ago, the provision was $3.1 billion, with $2.2 billion in charge-offs and an $821 million reserve build.
Average loans rose 5% YoY and up 3% quarter-over-quarter (QoQ); average deposits were up 6% YoY and +3% QoQ.
In CCB, debit and credit card sales volume increased by 7% year over year, and active mobile customers increased by 8% year over year. In CIB, Market revenue rose 15% year over year, with Fixed-Income Markets increasing 14% year over year and Equity Markets up 15% year over year in the quarter.
The CET1 capital ratio stood at 15%, and the advanced CET1 capital ratio was 15.1%. The bank&#8217;s capital distributions included a dividend per share of $1.40 and $7.1 billion of common stock net repurchases.
<h2 class="wp-block-heading">CEO Jamie Dimon&#8217;s Stance On Economy And Crypto</h2>
Jamie Dimon, Chairman and CEO, commented,&#8221; The U.S. economy remained resilient in the quarter. The finalization of tax reform and potential deregulation are positive for the economic outlook, however, significant risks persist – including from tariffs and trade uncertainty, worsening geopolitical conditions, high fiscal deficits and elevated asset prices. As always, we hope for the best but prepare the Firm for a wide range of scenarios.&#8221;
On the company conference call, Jamie Dimon stressed the importance of organic growth. He does not see a large deal that makes sense for the bank.
Dimon said the bank would be involved in stablecoins and JPMorgan deposit coins. He also mentioned that they do not feel the need to own a large language model (LLM).
<h2 class="wp-block-heading">Outlook</h2>
For the full year 2025, JPMorgan <a target="_blank" href="https://www.jpmorganchase.com/content/dam/jpmc/jpmorgan-chase-and-co/investor-relations/documents/quarterly-earnings/2025/2nd-quarter/360c049d-2061-4b87-ae11-e58a741956ad.pdf" rel="noreferrer noopener">expects</a> net interest income of approximately $95.5 billion, or $92 billion excluding Markets, and adjusted expenses of about $95.5 billion, all depending on market conditions. The Card Services net charge-off rate is projected at around 3.6%.
Price Action: JPM shares are down 0.64% at $286.97 premarket at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46414749/wells-fargos-net-interest-income-shrinks-in-q2-bank-trims-outlook" target="_blank" rel="noreferrer noopener">Wells Fargo&#8217;s Net Interest Income Shrinks In Q2, Bank Trims Outlook</a></li>
</ul>
Photo Courtesy lev radin via Shutterstock

Earnings

Guidance

JPMorgan Q2 Highlights: Investment Banking Revenue Jumps, Dimon Warns Of Tariffs And Geopolitical Risk

Former Labor Secretary Robert Reich is calling out the Trump administration over a sweeping deregulatory push at the Department of Labor. Reich says the move strips essential worker protections, even as President Donald Trump continues to brand himself as a champion of the American worker.
<h2 class="wp-block-heading">More Than 60 Rules On The Chopping Block</h2>
Reich <a href="https://x.com/RBReich/status/1942671313149042824">took to X</a> on July 8 to criticize what he called a direct attack on labor rights. "Trump&#8217;s Labor Department is gutting more than 60 regulations," he wrote, listing key protections including &#8220;minimum wage &amp; overtime pay for in-home care workers,&#8221; &#8220;organizing rights for migrant farmworkers,&#8221; and &#8220;penalties for companies that don't maintain a safe workplace.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
He ended the post with a sarcastic jab: "The ‘pro-worker' president strikes again."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump&#39;s Labor Department is gutting more than 60 regulations, including: -Minimum wage &amp; overtime pay for in-home care workers -Organizing rights for migrant farmworkers -Penalties for companies that don't maintain a safe workplace The "pro-worker" president strikes again.
&mdash; Robert Reich (@RBReich) <a href="https://twitter.com/RBReich/status/1942671313149042824?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The deregulation effort is being led by Labor Secretary Lori Chavez-DeRemer, who described the changes as a historic rollback of burdensome rules. "The Department of Labor is proud to lead the way by <a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">eliminating unnecessary regulations</a> that stifle growth and limit opportunity,&#8221; she said in a <a href="https://www.dol.gov/newsroom/releases/osec/osec20250701-0">statement</a> on July 1. "These historic actions will free Main Street, fuel economic growth and job creation, and give American workers the flexibility they need to build a better future."
The department is proposing 63 deregulatory actions, including cutting back on diversity, equity and inclusion efforts, removing certain safety rules in mining, and scrapping affirmative outreach requirements for programs that support workers with employment barriers.
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
Deputy Labor Secretary Keith Sonderling called the move "unprecedented," adding that, "While the previous administration prioritized expanding the size of government over job and wage growth, President Trump is focused on unleashing the greatest economic comeback in American history."
Critics say many of the rules being scrapped were put in place to protect the country's most vulnerable workers. The cuts build on 37 similar actions from Trump's first term and follow a new <a href="https://www.whitehouse.gov/fact-sheets/2025/01/fact-sheet-president-donald-j-trump-launches-massive-10-to-1-deregulation-initiative/">executive order</a> that requires eliminating 10 regulations for every new one issued.
Reich, who served under President Bill Clinton, has long warned that Trump's pro-worker image doesn't match his policies. The latest move, he argues, is more proof.
On the same day, Reich also pointed to the broader consequences of Trump's federal workforce policies: "Trump's <a href="https://www.benzinga.com/news/politics/25/07/46313304/trumps-federal-job-cuts-gets-supreme-court-go-ahead-doge-outpaces-big-tech-in-layoffs-across-us-bureaucracy">firings at federal agencies</a> have upended the lives of thousands of workers," he <a href="https://x.com/RBReich/status/1942693524195184703">wrote</a>. "These are the people who oversee air safety, food and drug safety, disaster response, public health, and much more."
Read Next:
<ul class="wp-block-list">
<li>This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

The 'Pro-Worker' President Strikes Again'—Ex-Labor Secretary Slams Trump's Labor Department For Gutting Over 60 Worker Protections

RAPT

RAPT Therapeutics Shares Resume Trade

CYCC

Cyclacel Pharmaceuticals Shares Resume Trade

Macro Economic Events

Global

Economics

Reuters Cites Brazil's Suzano Exec Saying Consumer In North America Will Have To Bear The Additional Cost Stemming From Tariffs

<ul>
<li>The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR &#xAE;, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors</li>
<li>Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030</li>
<li>Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus on predicting the efficacy, safety and biomarker signatures associated with those potential treatments</li>
<li>Platform successfully guided FDA-cleared Phase 1B/2 trial design for LP-184 + olaparib in triple-negative breast cancer</li>
</ul>
Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR&#xAE; platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.lanternpharma.com%2Fnews-1%2Fnews%2Fnews-details%2F2025%2FLantern-Advances-Drug-Candidate-LP-184-with-IND-Clearance-for-Phase-1b2-Clinical-Trial-in-Triple-Negative-Breast-Cancer-TNBC-2025-3ZfXads1GN%2Fdefault.aspx&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=achieved+FDA+clearance+for+a+Phase+1B%2F2+clinical+trial+in+triple-negative+breast+cancer+%28TNBC%29&amp;index=1&amp;md5=018505482c93aeed3a9a3d6255d12b3c">achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC)</a>, focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy.
In a peer-reviewed study published in Frontiers in Oncology, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.3389%2Ffonc.2025.1577468&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=Clinical+outcomes+of+DNA-damaging+agents+and+DNA+damage+response+inhibitors+combinations+in+cancer%3A+a+data-driven+review&amp;index=2&amp;md5=decb84403c612e661b24bdd68f046d29">Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review</a>, Lantern Pharma researchers systematically analyzed 221 DDA-DDRi combination-arm clinical trials, involving 22 DDAs and 46 DDRis, to develop this module. The study categorized DDAs into eight subclasses (e.g., alkylating agents, interstrand cross-linkers) and DDRis into 14 subclasses (e.g., PARP, ATR, WEE1 inhibitors). From these, 89 trials with interpretable outcomes were scored for clinical effectiveness, safety, and biomarker-driven responses, providing a robust dataset to train the AI module.1
Transforming Cancer Combination Therapy Development
The new AI module represents a paradigm shift in precision oncology, leveraging machine learning to predict which drug combinations will be most effective for specific patient populations while minimizing toxicity risks. This data-driven approach has already demonstrated its value by successfully guiding the design of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.lanternpharma.com%2Fnews-1%2Fnews%2Fnews-details%2F2025%2FLantern-Advances-Drug-Candidate-LP-184-with-IND-Clearance-for-Phase-1b2-Clinical-Trial-in-Triple-Negative-Breast-Cancer-TNBC-2025-3ZfXads1GN%2Fdefault.aspx&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=Lantern%27s+FDA-cleared+Phase+1B%2F2+clinical+trial+combining+LP-184+with+olaparib+in+triple-negative+breast+cancer&amp;index=3&amp;md5=944624f8b7c28bae6c8c8c6a7b5026be">Lantern's FDA-cleared Phase 1B/2 clinical trial combining LP-184 with olaparib in triple-negative breast cancer</a> (TNBC).

LTRN

Lantern Pharma Launches AI Module Trained On 221 Clinical Trials To Predict Efficacy Of DNA-Damaging Agent Combinations; Platform Already Guided FDA-Cleared Phase 1B/2 Trial In Triple-Negative Breast Cancer

Small Cap Consumer Research analyst Eric Beder reiterates Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

Analyst Ratings

Small Cap Consumer Research Reiterates Buy on Lands' End, Maintains $20 Price Target

Kairos Pharma Shares Resume Trade

RAPT Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 29.1%

Cyclacel Pharmaceuticals Shares Resume Then Halt Again On Circuit Breaker, Now Up 82.5%

RBC Capital analyst Elvira Scotto reiterates Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Outperform and maintains $63 price target.

RBC Capital Reiterates Outperform on Williams Companies, Maintains $63 Price Target

Oppenheimer analyst Michael Wiederhorn maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Outperform and lowers the price target from $85 to $51.

Oppenheimer Maintains Outperform on Centene, Lowers Price Target to $51

Reuters Cites Brazil's Suzano Exec Saying Brazil Represents 83% Of The Total Hardwood Pulp That U.S. Imports In A Given Year, That's A Relevant Number; Suzano Itself Will Find Ways Of Selling Those Those Products To Other Markets; But The Best Outcome Obviously Is Keeping The Relationships We Have Established For Several Years In North America; It's Very Hard To Predict From Our Side What Will Come, The The Lack Of Visibility Of The Next Steps Is A Factor

RBC Capital analyst Elvira Scotto reiterates Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Outperform and maintains $205 price target.

TRGP

RBC Capital Reiterates Outperform on Targa Resources, Maintains $205 Price Target

Oppenheimer analyst Tyler Batory maintains PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Outperform and raises the price target from $125 to $132.

Oppenheimer Maintains Outperform on PulteGroup, Raises Price Target to $132

Kairos Pharma Shares Halted On Circuit Breaker To The Downside, Stock Now Up 124.8%

Mizuho analyst John Roberts maintains Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) with a Outperform and raises the price target from $52 to $59.

Mizuho Maintains Outperform on Corning, Raises Price Target to $59

Press Releases

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

Health Care

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women's Health Innovation

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré's DARE to PLAY Sildenafil Cream

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson (NYSE: MCK) Sends "FOCUSfactor" Exploding Across North America – More Stocks Inside

Comments

Dare Bioscience

Dare Bioscience (DARE) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL